Management of panic disorder (Q36106827)

12 August 2017

1 reference

title

Management of panic disorder. (English)

1 reference

12 August 2017

Malcolm Lader

1

1 reference

12 August 2017

publication date

1 March 2005

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

259-266

1 reference

Panic attacks in the community. Social morbidity and health care utilization

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

The cross-national epidemiology of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

The role of life events in the onset of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

Sertraline treatment of panic disorder: results of a long-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

Interactive model of therapeutic response in panic disorder: moclobemide, a case in point

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

Alprazolam extended-release in panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

Does brief dynamic psychotherapy reduce the relapse rate of panic disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.5.2.259

21 January 2018

Identifiers

DOI

10.1586/14737175.5.2.259

1 reference

12 August 2017

1 reference